Compare CERT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2021 |
| Metric | CERT | ATAI |
|---|---|---|
| Price | $6.65 | $4.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $12.22 | ★ $15.57 |
| AVG Volume (30 Days) | 3.0M | ★ 4.5M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | $308,000.00 |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $5.73 | $285.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $6.04 | $1.15 |
| 52 Week High | $15.38 | $6.73 |
| Indicator | CERT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 54.40 |
| Support Level | $6.04 | $3.42 |
| Resistance Level | $11.53 | $4.40 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 40.20 | 64.64 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.